Correlation between SLCO1B1 gene polymorphism and statin efficacy in patients with hyperlipidemia

Cai Qibo; Ding Qi; Guo Jiading; Ren Zhanjun; Du Xin; Li Yadong; Zhang Zhilong

doi:10.3969/j.issn.1674-7151.2024.04.015

Abstract：Objective To analyze the correlation between the polymorphism of solute carrier organic anion transporter family member 1B1(SLCO1B1)gene and the therapeutic effect of statin therapy in patients with hyperlipidemia in Qiqihar area,Heilongjiang Province.Methods The 100 patients with dyslipidemia or taking statins in the Third Affiliated Hospital of Qiqihar Medical College from January to June 2024 were selected as study objects.Genomic DNA was extracted from all patients,and the SLCO1B1 gene polymorphism was determined using PCR-fluorescence probe method,and the allele frequency and genotype frequency were statistically compared.According to the therapeutic effect of statins,the patients were divided into poor efficacy group(18 cases),normal efficacy group(69 cases)and good efficacy group(13 cases).The genotype frequency distribution of SLCO1B1 among all groups was statistically and compared.Results SLCO1B1 genotype frequency distribution:the genotype frequencies of type *1b/*1b,type *1a/*1b,type *1b/*15,type *1a/*1a,type *1a/*15 and type *15/*15 were 43.0%,30.0%,16.0%,6.0%,3.0%and 2.0%.The genotype frequencies of type *1a/*5,type *5/*5 and type *5/*15 were all 0%.There was no statistical significance in the difference of genotype distribution in poor efficacy group,normal efficacy group and good efficacy group,and the overall distribution was uniform.The normal risk genotype *1b had the highest allele frequency(65.0%),followed by the moderate risk genotype *1a(allele frequency was 23.5%),and the high-risk genotype *15 had the lowest allele frequency(11.5%).Conclusions The patients with hyperlipidemia in Qiqihar area are suitable for statin therapy.By adjusting the frequency and dosage of medication based on genotype,clinical efficacy could be ensured and adverse reactions could be reduced.